November 18, 2026
Health news, explained with evidence
LIVE

Rethinking Metabolic Risk in Lean Patients with MASLD

🧠 AI Analysis 1 min read 👁 0

Recent analysis highlights the clinical oversight of metabolic dysfunction-associated steatotic liver disease in patients with a normal body mass index.

🧠AI Analysis

Key points

  • BMI is an insufficient surrogate for overall metabolic health.
  • Lean MASLD represents a clinically significant minority of cases.
  • Reliance on obesity-centered screening may lead to missed diagnoses.

A recent evaluation published in the JAMA Network challenges the traditional clinical reliance on body mass index (BMI) as the primary indicator for metabolic dysfunction-associated steatotic liver disease (MASLD). While excess body weight is a recognized driver of the global MASLD epidemic, focusing exclusively on body size can obscure significant health risks in patients who fall within a normal weight range.

The findings emphasize that a substantial subset of individuals develops MASLD despite not meeting the clinical criteria for obesity. This condition, often referred to as lean MASLD, demonstrates that a normal BMI does not automatically equate to a low risk of liver-related complications or metabolic dysfunction.

What to know: Clinical assessments should look beyond BMI to identify metabolic risks in patients. Always consult with a healthcare professional regarding individual screening for liver health, as body weight alone may not provide a complete picture of internal metabolic function.

Source JAMA Network — jamanetwork.com/journals/jama/fullarticle/2854675 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.